Skip to main content
Mehrdad Arjomandi, MD, Pulmonology, San Francisco, CA

MehrdadArjomandiMD

Pulmonology San Francisco, CA

Asthma & COPD, Critical Care Medicine, Occupational & Environmental Lung Disease

Professor of Pulmonary and Critical Care Medicine, University of California San Francisco

Dr. Arjomandi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Arjomandi's full profile

Already have an account?

  • Office

    4150 Clement Street
    Bldg 203/Rm 3A-20/Mailstop 111D
    San Francisco, CA 94115
    Phone+1 415-221-4810
    Fax+1 415-379-5538

Education & Training

  • University of California (San Francisco)
    University of California (San Francisco)Fellowship, Pulmonary Disease and Critical Care Medicine, 2000 - 2003
  • UCLA David Geffen School of Medicine/UCLA Medical Center
    UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 1996 - 1999
  • Stanford University School of Medicine
    Stanford University School of MedicineClass of 1996

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 1998 - 2026
  • American Board of Internal Medicine Critical Care Medicine
  • American Board of Internal Medicine Pulmonary Disease

Awards, Honors, & Recognition

  • Clean Air Award- Research Category Breathe California, 2015

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • E-cigarettes Versus Nicotine Patches for Perioperative Smoking Cessation: A Pilot Randomized Trial  
    Mehrdad Arjomandi, MD, PeerJ
  • Cardiovascular Function and Ozone Exposure: The Multicenter Ozone Study in oldEr Subjects (MOSES)  
    John R. Balmes, Philip A. Bromberg, Mark W. Frampton, Mehrdad Arjomandi, ScienceDirect

Press Mentions

  • Innovative Risk Score Tool Effectively Predicts Future Risk of Hospitalization for Pulmonary Disease Patients
    Innovative Risk Score Tool Effectively Predicts Future Risk of Hospitalization for Pulmonary Disease PatientsMay 21st, 2018

Grant Support

  • Osteopontin In Oxidative Injury And Airway Remodeling In AsthmaNational Heart, Lung, And Blood Institute2006–2010